Anti-Human IL4 & IL13 Bispecific Reference Antibody (Romilkimab, RUO)

Description: Research Grade Romilkimab (BS10014) is a humanized monoclonal antibody detecting IL13 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human.
Highlights:
• Multi-Application — Validated across multiple applications.
Host species: Humanized
Isotype: [VH-VH'-H-Gamma1-VL-VL'-C-kappa]-dimer
Species reactivity: Human
Immunogen:
Form: Liquid
Storage instructions:
Storage buffer: 0.01M PBS, pH7.4.
Concentration: 1mg/ml
Purity: >95% as determined by SDS-PAGE.
Clonality: Monoclonal
Applications: Research Grade Biosimilar
Target: IL13, NC30, Interleukin-13, IL-13, Binetrakin, B-cell stimulatory factor 1, Pitrakinra, Lymphocyte stimulatory factor 1, IL-4, BSF-1, IL4, Interleukin-4
Purification: Protein A/G purified from cell culture supernatant.
Endotoxin level: <1EU/mg, determined by LAL gel clotting assay
Expression system: Mammalian Cells
Stability and Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names: Bispecific, SAR156597, huTBTI3_2_1, CAS:1399584-78-1
Background: Romilkimab (SAR156597) is a chimeric humanized IG antibody that specifically targets IL-4 and IL13.
Note: For research use only. Not suitable for clinical or therapeutic use.